Navigation Links
Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C
Date:11/5/2007

P., Ph.D., Monash University, Melbourne, Australia. "The results of the Phase 2b trial suggest that Albuferon may have the potential to offer a therapeutic alternative with fewer lost days of work and less impairment of health-related quality of life on treatment, compared with peginterferon alfa-2a, with at least comparable efficacy and safety. We look forward to further evaluation of Albuferon's impact on patient quality of life in the ongoing Phase 3 trials."

In the open-label, multi-center, active-controlled Phase 2b trial, 458 treatment-naive patients with genotype 1 chronic hepatitis C were randomized to four treatment groups: Albuferon 900 mcg every two weeks, Albuferon 1200 mcg every two weeks, Albuferon 1200 mcg every four weeks, and peginterferon alfa-2a 180 mcg once a week. All patients received weight-based oral ribavirin daily. The trial included 48 weeks of treatment, and the primary efficacy endpoint was SVR, defined as undetectable viral load (HCV RNA<10 IU/mL) at 24 weeks following completion of treatment. Health-related quality of life was assessed using the Short Form 36 (SF-36) health survey. SF-36 is a validated patient-reported outcomes instrument, consisting of 36 questions used to measure the health status of patients with chronic hepatitis C. The 36 questions result in an 8-scale health profile including: physical function, physical role limitations, vitality, general health perceptions, pain, social function, emotional role limitations, and mental health. Summaries of the combined physical and mental component measures were also used in the assessment.

"Strongly positive overall quality-of-life results were observed for the Albuferon treatment groups, and they were strongest among patients receiving the Albuferon 900-mcg dose every two weeks," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "This Albuferon treatment group achieved a statistically significant reduction in the number of missed w
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 International Isotopes Inc. ... fiscal year ended December 31, 2014.  The Company reports ... net loss, and positive cash flow for the year ... revenue in 2014 was approximately $7.5 million compared to ... of approximately 10%.  With the exception of the radiological ...
(Date:4/1/2015)... , April 1, 2015 ... ), a clinical-stage pharmaceutical company focused on the development ... patient has been enrolled in its Glucose Clamp Study. ... Texas Health Science Center at San Antonio ... under the supervision of Professor Ralph DeFronzo . ...
(Date:4/1/2015)... , April 1, 2015  Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of an offering of $60.0 million aggregate principal ... (the "notes") in a private placement to qualified ... Securities Act of 1933, as amended (the "Act"). ...
Breaking Medicine Technology:International Isotopes Inc. Announces 2014 Year End Financial Results 2International Isotopes Inc. Announces 2014 Year End Financial Results 3International Isotopes Inc. Announces 2014 Year End Financial Results 4International Isotopes Inc. Announces 2014 Year End Financial Results 5International Isotopes Inc. Announces 2014 Year End Financial Results 6International Isotopes Inc. Announces 2014 Year End Financial Results 7Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 2Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 7
... NEW YORK, Sept. 13, 2011 IMMUNE ... based Therapeutics for the treatment of inflammatory diseases and ... M.D., Ph.D., to the position of Chief Medical Officer.  ... pivotal  role in the development of Bertilimumab, IMMUNE,s phase ...
... DIEGO, Sept. 13, 2011 Sequenom, Inc. (NASDAQ: ... solutions, today announced the Company,s participation at the UBS Global ... in New York City September 19-21, 2011. ... Development, will present on Monday, September 19, 2011 beginning at ...
Cached Medicine Technology:IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 2IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 3Sequenom Announces Participation at UBS Global Life Sciences Conference 2
(Date:4/1/2015)... Alcohol Awareness Month , The National Council ... sponsoring Alcohol Awareness Month every April since 1987. ... understating of alcohol-related issues. During the month of ... and alcoholism. , For the Health of It: Early ... for Alcohol Awareness Month. During April, focus is ...
(Date:4/1/2015)... Royal River Natural Foods, a locally-owned independent natural health store ... amino acid creatine, which athletes typically use to build strength ... The report is part of the April 2015 ... Royal River Natural Foods publishes each month as a free ... in nutrition science. Also in the April issue, vitamin D ...
(Date:4/1/2015)... One year ago today, the USO cut the ribbon on ... States and changed the landscape on Naval Support Activity Bethesda ... more than 100,000 troops and military families in the last ... injured and their families, proving to be a valuable resource ... the country. After opening its doors on the campus that ...
(Date:4/1/2015)... Bird B Gone, the leader in ... now offers a complete line of Bird Netting ... netting products quickly, safely and efficiently. , Having the ... bird netting installation. It’s important to determine exactly what ... a project. This includes deciding whether to use all ...
(Date:4/1/2015)... CA, March 24, 2015 (PRWEB) April 01, 2015 ... by many, the most extreme jungle adventure you could ever ... many as 23 days. Endorsed by the Philippine Department of ... people have visited the rainforest, but very few people have ... Bergman, Chief Adventure Officer. , Armed with nothing more than ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Releases Guide to Handling Alcoholism in the Family for Alcohol Awareness Month 2Health News:Narconon Arrowhead Releases Guide to Handling Alcoholism in the Family for Alcohol Awareness Month 3Health News:New Study Finds Strength-Building Supplement Improves Circulation, Retailer Reports 2Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 2Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 3Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 4Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 5Health News:Bird B Gone Now Carries Complete Bird Netting Hardware 2Health News:Bird B Gone Now Carries Complete Bird Netting Hardware 3
... ,In the 30 years since the first reported cases ... have made extraordinary advances in understanding, treating and preventing ... the National Institute of Allergy and Infectious Diseases (NIAID), ... build on those successes to control and, ultimately, end ...
... New England Journal of Medicine , physicians and ... successful treatment of three young children who were suffering ... with enterohemorrhagic Escherichia coli (EHEC). The infections ... the current wave of infections that have already claimed ...
... a world-leading publisher of scientific, technical and medical information ... of a new journal, International Journal of Paleopathology ... quarterly, the first issue of the journal is now ... copies of the first issue will be available at ...
... Researchers at Children,s Hospital Boston and Google.org have found web-based ... early detection and monitoring of outbreaks of dengue, an emerging ... search data allows the capture of disease-related queries in near ... more than 100 countries affected by dengue respond more quickly ...
... , MONDAY, May 30 (HealthDay News) -- Although stress ... person,s risk for developing the disease in the first place, ... than 100,000 nurses each, ranging in age from 24 to ... Those examined were asked about their levels of stress both ...
... ST. PAUL, Minn. Contrary to earlier reports, a new ... person,s risk of developing multiple sclerosis (MS). The research is ... Neurology , the medical journal of the American Academy of ... have been shown to increase the risk of MS episodes, ...
Cached Medicine News:Health News:Antibodies successful in the treatment of the hemolytic-uremic syndrome from EHEC 2Health News:Elsevier launches new journal: International Journal of Paleopathology 2Health News:Searching the web for dengue 2
... cool and your patient warm, with ... cooling system.,Designed around the Coanda Effect, ... localized air flow around your torso's ... during the heat and stress induced ...
... System is designed to provide excellent capture ... carotid stenting interventions. The ACCUNET is a ... utilizes rapid exchange technology so that the ... catheter manipulations. It is available in both ...
... The Precision PCx point of ... a whole-blood, patient-side testing system for ... use, the system provides fast, accurate ... hospital and laboratory information systems enables ...
Representing the next step in the evolution of point-of-care testing, the i-STAT 1 Analyzer uses one platform to perform glucose strip testing along with all i-STAT test cartridges....
Medicine Products: